Portola Pharmaceuticals Inc
Seattle Genetics and Bristol-Myers Initiate ADCETRIS Trial
On December 23, 2015, Seattle Genetics and Bristol-Myers Squibb announced the initiation of Phase 1 and 2 clinical trials of ADCETRIS.
Why Portola Pharmaceuticals Rose 8.09% on January 4
On January 4, Portola Pharmaceuticals stock closed at $19.38, an ~8.09% increase from its prior close of $17.93 on January 3,
Portola Pharmaceuticals Stock Rose after Its Q3 2018 Results
On November 8, after Portola Pharmaceuticals released its third-quarter financial results, the stock price rose 21.41%.
How Is Johnson & Johnson’s Xarelto Positioned after 3Q17?
In 3Q17, Johnson & Johnson’s (JNJ) Xarelto generated revenues of $635 million, a ~20% increase on a year-over-year (or YoY) basis and a 1% decline quarter-over-quarter.
IBB Remained Flat Last Week
The iShares Nasdaq Biotechnology ETF (IBB) gained marginally by 0.57% in the week ending September 18, 2015.
Biogen: An Investor’s Overview to a Leading Biotech Company
One of the world’s leading biotechnology companies, Biogen specializes in manufacturing and marketing therapies to treat serious ailments related to the nervous system, immune system, and blood.